Prokinetic agents for lower gastrointestinal motility disorders

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Motility disorders of the lower gastrointestinal tract are a significant clinical challenge.
• Current prokinetic agents have limitations in efficacy and side effect profiles.

Purpose of the Study:

• To review the current landscape of prokinetic agents for gastrointestinal motility disorders.
• To highlight agents with potential for colonic motility disorders.

Main Methods:

• Literature review of prokinetic agents and their effects on gastrointestinal motility.
• Analysis of clinical applications and patient outcomes for various prokinetic drugs.

Main Results:

• Cholinergic agonists (e.g., bethanechol) and dopamine antagonists (e.g., domperidone) primarily affect the proximal GI tract.
• Naloxone shows potential for irritable bowel syndrome and pseudo-obstruction.
• Erythromycin (motilin agonist) aids diabetic gastroparesis and colonic pseudo-obstruction.
• Cisapride demonstrates significant promise for colonic motility disorders, improving postoperative ileus and chronic constipation.

Conclusions:

• Cisapride is a promising agent for colonic motility disorders, including constipation and postoperative ileus.
• Further understanding of GI motility may lead to more effective prokinetic therapies.
• Identifying patients who benefit from specific prokinetic agents can guide surgical management decisions.